Fulgent Genetics, Inc. (FLGT)

20,10 +0,07 (+0,35%) Börsenschluss: 04:00PM EDT

Fulgent Genetics, Inc.

4399 Santa Anita Avenue
El Monte, CA 91731
United States
626-350-0537
https://www.fulgentgenetics.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 1.184

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ming Hsieh	Chairman & CEO	2,31M	N/A	1956
Mr. Jian Xie	COO & President	868,74k	N/A	1966
Mr. Paul Kim	Chief Financial Officer	879,61k	N/A	1967
Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D.	Chief Scientific Officer & Laboratory Director	720,7k	N/A	1967
Ms. Natalie Prescott	General Counsel & Chief Privacy Officer	N/A	N/A	N/A
Ms. Doreen Ng	VP of Operations & Compliance and GM of Houston Office	N/A	N/A	N/A
Mr. Jakub Sram	Vice President of Business Development & Sales	N/A	N/A	N/A
Ms. Ellen Tsui	Vice President of Human Resources	N/A	N/A	N/A
Mr. Brandon Perthuis	Chief Commercial Officer	N/A	N/A	N/A
Dr. Lawrence M. Weiss M.D.	Chief Medical Officer	N/A	N/A	1957

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Corporate Governance

Fulgent Genetics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 2, Vorstand: 7, Shareholderrechte: 4, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.